Continuation of No Dividends and Retention of Earnings for the Foreseeable Future
First written in FY2016. 17 of 18 entries say "Restated". Latest entry: 2026-06-01.
The whole theme swung hardest in 2025: 2 of 19 companies on the "Worse" side.
31 other companies' latest entry also says "Restated".
- 2026-06-01RestatedGeneral Meetings of Shareholders
「However, as the Company remains at the stage of continuously conducting basic research, drug discovery research and drug development toward the future launch of cancer therapeutics, it is prioritizing the retention of internal funds and securing research and development funds for the time being.」
The policy of prioritizing the retention of internal funds and securing research and development funds for the time being was reiterated. - FY2026-H1RestatedAnnual report
「1. Dividends paid: Not applicable.」
No dividends were paid during the interim consolidated accounting period, and the company continues to have no dividend. - FY2025RestatedAnnual report
「For the time being, the company is working to retain internal funds and prioritizing the securing of research and development funding.」
The company is again paying no dividend for the current period and has reaffirmed its policy of prioritizing retained earnings and securing funds for research and development for the time being. - FY2023-Q3RestatedAnnual report
「1. Dividends paid: Not applicable.」
No dividends were paid during the nine-month cumulative period, and the company continues to have no dividend. - FY2023-Q1RestatedAnnual report
「Dividend payments Not applicable.」
No dividends were paid during the quarter, and the company continues to have no dividend. - FY2022-Q3RestatedAnnual report
「Dividend payments Not applicable」
No dividends were paid during the nine-month cumulative period, and the company continues to have no dividend. - FY2022-Q1RestatedAnnual report
「Dividend payments during the three-month cumulative consolidated period ended 30 June 2021 (from 1 April 2021 to 30 June 2021): Not applicable.」
No dividends were paid during the quarter, and the company continues to have no dividend. - FY2021-Q2RestatedAnnual report
「Dividend payments Not applicable.」
No dividends were paid during the quarter, and the company continues to have no dividend. - FY2021-Q1RestatedAnnual report
「Dividend payments Not applicable.」
No dividends were paid during the quarter, and the company continues to have no dividend. - FY2020-Q3RestatedAnnual report
「Dividend payments during the nine-month cumulative consolidated period ended 31 December 2019 (from 1 April 2019 to 31 December 2019): Not applicable.」
No dividends were paid during the cumulative period, and the company continues to have no dividend. - FY2020-Q2RestatedAnnual report
「Dividend payments during the six-month cumulative consolidated period ended 30 September 2019 (from 1 April 2019 to 30 September 2019): Not applicable.」
No dividends were paid during the quarter, and the company continues to have no dividend while prioritizing research and development. - FY2020-Q1RestatedAnnual report
「Dividend payments during the three-month cumulative consolidated period ended 30 June 2019 (from 1 April 2019 to 30 June 2019): Not applicable.」
No dividends were paid during the quarter, and the company continues to have no dividend while prioritizing research and development. - FY2018RestatedAnnual report
「However, as the company is currently at the stage of continuously conducting basic research, drug discovery research and pharmaceutical development toward launching future cancer treatments, it is prioritizing the retention of internal funds and securing research and development funding for the time being.」
The company is again paying no dividend for the current period and has reaffirmed its policy of prioritizing retained earnings and securing funds for research and development for the time being. - FY2018-Q3RestatedAnnual report
「Dividend payments during the nine-month cumulative consolidated period ended 31 December 2017 (from 1 April 2017 to 31 December 2017): Not applicable.」
No dividends were paid during the nine-month cumulative consolidated period, and the company continues to have no dividend. - FY2018-Q2RestatedAnnual report
「Dividends paid during the six-month consolidated cumulative period from 1 April 2017 to 30 September 2017: Not applicable.」
No dividends were paid during the six-month consolidated cumulative period, and the company continues not to pay dividends. - FY2017RestatedAnnual report
「As the company is currently at the stage of continuously conducting basic research, drug discovery research, and pharmaceutical development toward the future launch of cancer therapeutics, it is retaining earnings for the time being and prioritizing the provision of funds for research and development.」
The company is again paying no dividend for the current period and has reaffirmed its policy of prioritizing retained earnings and securing funds for research and development for the time being. - FY2017-Q3RestatedAnnual report
「Dividend payments Not applicable.」
No dividends were paid during the nine-month period ended 31 December of the current fiscal year, and the company continues not to pay dividends while prioritizing research and development. - FY2016First statedAnnual report
「As the company is currently at the stage of continuously conducting basic research, drug discovery research, and pharmaceutical development toward the future launch of cancer therapeutics, it is retaining earnings for the time being and prioritizing the provision of funds for research and development.」
There was no dividend for the period, reflecting a shareholder returns policy that prioritizes research and development.